CAI
Caris Life Sciences, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Coatue Management ✦ | 10.14M | New | $271.00M | 0.8% | New | 1 | SEC ↗ ×2 |
| 2 | Fidelity (FMR) ✦ | 8.63M | n/a | $230.63M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 3 | T. Rowe Price ✦ | 6.76M | New | $180.65M | 0.0% | New | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 3.51M | New | $93.87M | 0.1% | New | 1 | SEC ↗ |
| 5 | Capital World Investors ✦ | 999.95K | New | $26.72M | 0.0% | New | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 458.48K | New | $12.25M | 0.0% | New | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 375.00K | New | $10.02M | 0.0% | New | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 341.57K | New | $9.13M | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | BlackRock ✦ (passive) | 309.10K | n/a | $8.26M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 10 | Geode Capital Management ✦ (passive) | 235.23K | New | $6.29M | 0.0% | New | 1 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passive) | 150.00K | n/a | $4.01M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Adage Capital Partners ✦ | 150.00K | New | $4.01M | 0.0% | New | 1 | SEC ↗ |
| 13 | Soros Fund Management ✦ | 50.00K | New | $1.34M | 0.0% | New | 1 | SEC ↗ |
| 14 | ARK Investment Management ✦ | 47.05K | New | $1.26M | 0.0% | New | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 37.87K | New | $1.01M | 0.0% | New | 1 | SEC ↗ ×2 |
| 16 | D. E. Shaw & Co. ✦ | 7.50K | New | $200,400 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Coatue Management | $271.00M | 0.8% |
| T. Rowe Price | $180.65M | 0.0% |
| Millennium Management | $93.87M | 0.1% |
| Capital World Investors | $26.72M | 0.0% |
| Point72 Asset Management | $12.25M | 0.0% |
| Norges Bank | $10.02M | 0.0% |
| Citadel Advisors | $9.13M | 0.0% |
| Geode Capital Management | $6.29M | 0.0% |
| Adage Capital Partners | $4.01M | 0.0% |
| Soros Fund Management | $1.34M | 0.0% |
| ARK Investment Management | $1.26M | 0.0% |
| Marshall Wace | $1.01M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 200 holders, 153.41M shares, $2.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.50K sh · $238,626
Officer, Director · 400.00K sh · $12.13M
Officer · 119.21K sh · $2.95M
Officer · 393.10K sh · $9.73M
Officer · 84.90K sh · $2.15M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology